Gene and cell transfer for specific immunotherapy.
The realisation that human tumor cells may express and process tumor specific and tumor associated antigens has increased interest in immunotherapeutic approaches to cancer treatment. This interest has been coupled with a burgeoning ability to genetically modify tumor cells and components of the immune system, in an effort to maximize the anti-neoplastic response. In a number of settings, gene modified tumor vaccines, cytotoxic T cells and dendritic cells are producing both immunomodulation and clinically evident benefits. Continued exploration of this approach seems well justified.
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA. mkbrenne@msmail.his.tch.tmc.edu
M K
MK
Brenner
H E
HE
Heslop
C M
CM
Rooney
D000256:Adenoviridae / Q000235:genetics; D017209:Apoptosis / Q000235:genetics; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D019496:Cancer Vaccines; D003713:Dendritic Cells / Q000637:transplantation; D020031:Epstein-Barr Virus Infections / Q000628:therapy; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D020350:Graft vs Tumor Effect; D004854:Herpesvirus 4, Human / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000008:administration & dosage / Q000235:genetics; D016393:Lymphoma, B-Cell / Q000628:therapy; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D014411:Neoplastic Stem Cells / Q000276:immunology / Q000637:transplantation; D013602:T-Lymphocytes, Cytotoxic / Q000637:transplantation
D019496:Cancer Vaccines; D007376:Interleukin-2